Ryan Fischesser - Caribou Biosciences Vice Controller
| CRBU Stock | USD 2.02 0.04 2.02% |
Executive
Ryan Fischesser is Vice Controller of Caribou Biosciences
| Address | 2929 7th Street, Berkeley, CA, United States, 94710 |
| Phone | 510 982 6030 |
| Web | https://cariboubio.com |
Latest Insider Transactions
Ryan Fischesser Latest Insider Activity
Tracking and analyzing the buying and selling activities of Ryan Fischesser against Caribou Biosciences stock is an integral part of due diligence when investing in Caribou Biosciences. Ryan Fischesser insider activity provides valuable insight into whether Caribou Biosciences is net buyers or sellers over its current business cycle. Note, Caribou Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Caribou Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Ryan Fischesser over a month ago Insider Trading |
Caribou Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.2514) % which means that it has lost $0.2514 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.436) %, meaning that it created substantial loss on money invested by shareholders. Caribou Biosciences' management efficiency ratios could be used to measure how well Caribou Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.25 in 2024. Return On Capital Employed is likely to drop to -0.3 in 2024. Total Current Liabilities is likely to drop to about 23 M in 2024. Liabilities And Stockholders Equity is likely to drop to about 296.2 M in 2024Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Alpa Parikh | Lumos Pharma | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| John PharmD | Scpharmaceuticals | N/A | |
| Lisa MD | Seres Therapeutics | 65 | |
| RPh Young | Seres Therapeutics | 57 | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| JD Esq | Seres Therapeutics | 69 | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| MD FAAP | Lumos Pharma | N/A | |
Management Performance
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.25 |
Caribou Biosciences Leadership Team
Elected by the shareholders, the Caribou Biosciences' board of directors comprises two types of representatives: Caribou Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Caribou. The board's role is to monitor Caribou Biosciences' management team and ensure that shareholders' interests are well served. Caribou Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Caribou Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Amy CFA, Vice Communications | ||
| Cindy Hayashi, VP HR | ||
| Ryan Fischesser, Vice Controller | ||
| Jason MBA, Chief Officer | ||
| JD Esq, Chief Secretary | ||
| Timothy MBA, Chief Officer | ||
| Reigin Zawadzki, Chief Officer | ||
| Syed MD, Chief Officer | ||
| Rachel Haurwitz, CEO, CoFounder | ||
| Steven Kanner, Chief Officer | ||
| Ruhi MBA, Chief Officer | ||
| Justin Skoble, VP Operations | ||
| Daniel Poon, Vice Technology |
Caribou Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Caribou Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.25 | ||||
| Operating Margin | (16.67) % | ||||
| Current Valuation | (18.62 M) | ||||
| Shares Outstanding | 90.55 M | ||||
| Shares Owned By Insiders | 10.00 % | ||||
| Shares Owned By Institutions | 62.57 % | ||||
| Number Of Shares Shorted | 9.94 M | ||||
| Price To Book | 0.65 X | ||||
| Price To Sales | 15.94 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Caribou Stock Analysis
When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.